Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY - FEDBIZOPPS ISSUE OF JANUARY 26, 2019 FBO #6273
SOLICITATION NOTICE

A -- PREVENT Cancer Preclinical Drug Development Program

Notice Date
5/7/2018
 
Notice Type
Combine Synopsis/Solicitation
 
NAICS
541714 — Research and Development in Biotechnology (except Nanobiotechnology)
 
Contracting Office
Bldg 244, Room 112 Frederick MD 21702
 
ZIP Code
21702
 
Solicitation Number
N01CN77019-18
 
Response Due
6/21/2018
 
Point of Contact
Nicole Belanger, Contracting Officer, Phone 3016248754, - Mandie S. White, Contracting Officer, Phone 301-624-8756
 
E-Mail Address
belangern@mail.nih.gov, whitems@mail.nih.gov
 
Small Business Set-Aside
N/A
 
Description
The purpose of this solicitation is to procure Research & Development services to support the PREVENT Program in the areas of (1) in vivo development/animal efficacy/biomarker development, (2) preclinical product development and CGMP manufacturing of biopharmaceutical agents, and (3) toxicology/pharmacology testing. In order to meet the demands for all services in a timely and proactive manner, the NCI intends to award contracts that provide a suite of technical task support services, using the Indefinite Delivery-Indefinite Quantity (IDIQ) contract mechanism. Under the IDIQ mechanism, the NCI will award Task Orders for specific activities that meet technical requirements tailored for each identified PREVENT project's needs. While the overall suite of services listed is comprehensive, the intent is to provide individual services on a case-by-case basis for a diverse collection of candidate agents, rather than carry a single candidate product through an entire preclinical development pathway. These services are intended to help investigators in various scientific disciplines obtain critical data needed to advance their agents further through the PREVENT pipeline, acquire additional funding from other sources, gain prospective partnerships (either for further development or to support Phase I trials), fulfill regulatory requirements, and/or complete studies needed to apply for an IND and enter a Phase I trial. NOTE: THIS NOTICE MAY HAVE POSTED ON FEDBIZOPPS ON THE DATE INDICATED IN THE NOTICE ITSELF (07-MAY-2018). IT ACTUALLY APPEARED OR REAPPEARED ON THE FEDBIZOPPS SYSTEM ON 24-JAN-2019, BUT REAPPEARED IN THE FTP FEED FOR THIS POSTING DATE. PLEASE CONTACT 877-472-3779 or fbo.support@gsa.gov REGARDING THIS ISSUE.
 
Web Link
Link To Document
(https://www.fbo.gov/spg/HHS/NIH/FCRF2/N01CN77019-18/listing.html)
 
Record
SN05202317-F 20190126/190124230039 (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.